Comparison of the efficacy and safety between dezocine injection and morphine injection for persistence of pain in Chinese cancer patients: a meta-analysis

Abstract

The association between the efficacy and safety of dezocine injection and morphine injection for persistence of pain in patients with cancer had yielded controversial results. Therefore, we conduct a meta-analysis of existing observational published studies to assess the relationship between them among Chinese. We conducted a comprehensive research from the databases of PubMed, Web of Science, and Wan Fang Med Online for the related studies up to October 2016. Summary odds ratio (OR) with 95% confidence interval (95% CI) were calculated with the random effects model. Nine published studies comprising 333 dezocine injection patients and 321 morphine injection patients were included in this meta-analysis. Our results suggested that there was no statistical significance between dezocine injection and morphine injection at the case number of effective pain relief (EPR) [OR = 0.97, 95% CI (0.77–1.22), I2 = 0.0, P for heterogeneity = 1.000]. However, the rate of adverse drug reaction (ADR) caused by dezocine injection was 56% less than that caused by morphine injection, the difference was statistically significant [OR = 0.44, 95% CI (0.30–0.65), I2 = 0.0, P for heterogeneity = 0.980]. No between-study heterogeneity and publication bias were found. In conclusions, this meta-analysis indicates that there is no significant association on the efficacy of persistence of pain in patients with cancer between dezocine injection and morphine injection among Chinese. However, dezocine injection was with less ADR compared with morphine injection.

A Bioinformatics Research on Novel Mechanism of Compound Kushen Injection for Treating Breast Cancer by Network Pharmacology and Molecular Docking Verification

“…Studies have shown that radiotherapy and chemotherapy can increase the risk of myelodysplastic disorder and acute myeloid leukemia in BC patients, which means more pain for patients with poor body function and poor tolerability [2]. Traditional Chinese medicine (TCM), as a traditional medicine for adjuvant treatment of tumors, has the effect of improving the immune function and tumor microenvironment of the patients and reducing the toxicity of radiotherapy and chemotherapy, so as to improve the survival rate [3][4][5][6][7]. It is shown that compound Kushen injection (CKI), as a TCM compound preparation, has a good synergistic antitumor effect by inhibiting tumor cell proliferation and inducing differentiation.…”

Effect of Dezocine on the Ratio of Th1/Th2 Cytokines in Patients Receiving Postoperative Analgesia Following Laparoscopic Radical Gastrectomy: A Prospective Randomised Study

“…However, one meta-analysis reported that there is no significant difference between dezocine and morphine injections on the persistence of pain in patients with cancer among Chinese patients. 22 A pilot study by Zhu et al 13 showed that the analgesic efficacy of dezocine was similar to that of sufentanil. Dezocine combined with sufentanil can provide effective postoperative analgesia for PCIA in burn patients after escharectomy or tangential excision followed by autologous skin grafting.…”

“…35 Our findings demonstrate that the incidence of lethargy and PONV in Group D was significantly lower than the incidence in Group S. This difference was statistically significant ( P <0.05), suggesting that dezocine might be an antagonist of the μ receptor, without μ receptor agonist side effect, capable of relaxing the gastrointestinal smooth muscle and reducing the incidence of PONV. 36 Wang et al 22 revealed that the rate of adverse drug reactions caused by dezocine injection was 56% lower than that caused by morphine injection. A study by Bian et al 38 revealed that morphine and sufentanil may dose-dependently increase the contractile tension and contraction ability of isolated rat small intestine smooth muscle, but dezocine had no significant effect on intestinal smooth muscle contraction.…”

Dezocine inhibits cell proliferation, migration and invasion by targeting CRABP2 in ovarian cancer

“…For example, sevo urane has been revealed to function as an anti-tumor reagent in different types of cancer, including ovarian cancer [12][13][14]. As a representative opioid-receptor agonist/antagonist, dezocine has been widely used in clinical anesthesia and analgesics for postoperative cancer with minimal side effects [15][16][17]. Feng C et al previously report that dezocine could regulate the secretion of IL-12 and IL-10 in dendritic cells and enhance the activity of T cells during the maturation of dendritic cells, affecting immune function [18].…”